Aclasta
Postmenopausal osteoporosis (to reduce the risk of femur, vertebral and non-vertebral fractures, to increase bone mineral density); prevention of subsequent (new) osteoporotic fractures in men and women with fractures of the proximal femur; osteoporosis in men; prevention and treatment of osteoporosis caused by the use of corticosteroids; prevention of postmenopausal osteoporosis (in patients with osteopenia); Paget’s disease of bone.
Osteolytic, osteoblastic and mixed bone metastases of solid tumors and osteolytic foci in multiple myeloma, as part of combination therapy; hypercalcemia caused by a malignant tumor.
Active ingredient: zoledronic acid monohydrate.
Storage temperature 2-8 degrees.
Prescription medicine.